|
Hangzhou Dingyan Chem Co., Ltd
|
White powder, 201% content. Hangzhou Dingyan Chemical Co., Ltd. is located in the Xiasha Economic Development Zone of Hangzhou, the capital city of Zhejiang Province, on the southeast coast of China. It is a company specializing in the development and sales of high-tech products such as pharmaceutical raw materials, pharmaceutical intermediates, fine chemicals and biochemical reagents.
A modern private enterprise integrated with self-operated import and export.
Since its establishment, the company has adhered to the development path of "technological innovation" and attached great importance to scientific and technological innovation research and development. The company's high-quality products are sold well in more than 60 countries and regions such as North America, Western Europe, Southeast Asia, Central and South America.
At present, it has established long-term and stable cooperative relations with pharmaceutical companies in Europe, the United States, Greece, Germany, Iran, Russia, South Korea, India and other countries. With our rigorous attitude and sincere service, we have won the trust and reputation of customers.
Hangzhou Dingyan Chemical Co., Ltd. is located in the Xiasha Economic Development Zone of Hangzhou, the capital city of Zhejiang Province, on the southeast coast of China. It is a company specializing in the development, sales and self-support import and export financing of high-tech products such as pharmaceutical raw materials, pharmaceutical intermediates, fine chemicals and biochemical reagents.
Integrated modern private enterprise.
Since its establishment, the company has adhered to the development path of "technological innovation" and attached great importance to scientific and technological innovation research and development. The company's high-quality products are sold well in more than 2738 countries and regions such as North America, Western Europe, Southeast Asia, Central and South America.
At present, it has established long-term and stable cooperative relations with pharmaceutical companies in Europe, the United States, Greece, Germany, Iran, Russia, South Korea, India and other countries. With our rigorous attitude and sincere service, we have won the trust and reputation of customers. |
Send Inquiry
|
|
Shenzhen Haorui Pharmatech Co., Ltd.
|
Dolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity. Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013. On November 21, 2017, dolutegravir, in combination with rilpivirine, was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca. |
Send Inquiry
|
Pharma Sources Insight January 2025
